New drug M3554 targets Hard-to-Treat cancers in first human trial
NCT ID NCT06641908
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 32 times
Summary
This early-phase study tests a new drug called M3554 in people with advanced solid tumors, specifically soft tissue sarcoma and a type of brain cancer (glioblastoma). The main goal is to find a safe dose and check for side effects. About 52 participants will receive the drug intravenously and be monitored for around 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Antoine Lacassagne - Service d'Hématologie Oncologie
RECRUITINGNice, France
-
Centre Leon Berard - Service d'Oncologie Medicale
RECRUITINGLyon, France
-
Centre Oscar Lambret - cancerologie generale
RECRUITINGLille, France
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Institut Bergonié - Service d'Oncologie Médicale
RECRUITINGBordeaux, France
-
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc
WITHDRAWNNew York, New York, 10022, United States
-
National Cancer Center Hospital
RECRUITINGChūōku, Japan
-
Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey)
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
UZ Leuven
RECRUITINGLeuven, Belgium
-
Universitaetsspital Zuerich - Klinik fuer Neurologie
RECRUITINGZurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.